July 9, 2010 – Lantheus Medical Imaging Inc. announced this week that it has signed a new manufacturing and supply agreement with MDS Nordion to purchase molybdenum-99 (Mo-99), the parent isotope of technetium-99m (Tc-99m). Mo-99 is used in Lantheus Medical Imaging’s TechneLite generators, which are sold throughout the world, and which produce Tc-99m, a medical isotope widely used in nuclear medicine imaging.

Under terms of the new agreement, Lantheus will begin receiving additional supplies of Mo-99 on a weekly basis once the National Research Universal (NRU) reactor is back online, which is currently anticipated to be at the end of July 2010. The contract is in place until July 31, 2011.

“Our agreement with MDS Nordion is part of Lantheus Medical Imaging’s aggressive supply chain strategy to strengthen our Mo-99 supply by working with major suppliers around the world in helping to meet the medical isotope needs of our customers in North America,” said Don Kiepert, president and chief executive officer, Lantheus Medical Imaging Inc.

“This agreement represents MDS Nordion and Lantheus’ commitment to provide medical isotopes to the global nuclear medicine community,” said Steve West, chief executive officer, MDS Inc. “The Nordion team has been actively preparing for the NRU restart and we have taken the steps necessary to assume our role in the supply chain and resume the processing of isotopes for patients worldwide.”

Over 21 million doses of diagnostic radiopharmaceuticals were injected into patients in the United States during 2009. Of these, 65 percent were for cardiac exams, with the remaining for oncology, neurology and other applications. Tc-99m, which is the decay product of Mo-99, is the most commonly used medical radioisotope in the United States. At 16.7 million doses, Tc-99m accounted for 80 percent of all diagnostic radiopharmaceutical injections.

Tc-99m is used in Lantheus Medical Imaging’s TechneLite generators, which are distributed to radiopharmacies and hospitals as a source of Tc-99m for diagnostic imaging procedures. In diagnostic use, the Tc-99m is attached to a specific molecule and injected into the patient. The diagnostic medicine then travels to the site or organ of interest and a special camera is used to pick up the gamma rays emitted from the radioactive material in the body and to create images for diagnostic evaluation.


Related Content

News | Prostate Cancer

July 30, 2024 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time July 30, 2024
arrow
News | PET-CT

July 25, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET & PET-CT imaging ...

Time July 25, 2024
arrow
News | PET-CT

July 16, 2024 — A new research paper was published in Oncotarget's Volume 15 on June 20, 2024, titled, “Comparison of ...

Time July 16, 2024
arrow
News | Nuclear Imaging

June 20, 2024 — GE HealthCare joined the world’s top medical and academic institutions at the Society of Nuclear ...

Time June 20, 2024
arrow
News | PET-CT

June 13, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Time June 13, 2024
arrow
News | SPECT-CT

June 11, 2024 — A newly developed radiotracer can generate high quality and readily interpretable images of cardiac ...

Time June 11, 2024
arrow
News | Artificial Intelligence

May 30, 2024 — Paige, a global leader in end-to-end digital pathology solutions and artificial intelligence (AI) ...

Time May 30, 2024
arrow
News | Radiation Oncology

May 10, 2024 — Mariana Oncology, a fully integrated biotechnology company pioneering a new era of radiopharmaceutical ...

Time May 10, 2024
arrow
News | Prostate Cancer

May 2, 2024 — GT Medical Technologies, Inc. (GT MedTech), a medical device company with the mission of improving the ...

Time May 02, 2024
arrow
News | Proton Therapy

April 29, 2024 — Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, announced today ...

Time April 29, 2024
arrow
Subscribe Now